Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction

• Status: Unknown status
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate whether nicorandil as an adjunctive therapy for acute myocardial infarction (AMI) reduces reperfusion injury.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xuzhou Central Hospital
• Treatments: Nicorandil

Criteria

Inclusion Criteria:

• Acute ST Segment Elevation Myocardial Infarction (ASTEMI) defined as typical chest pain lasting >30min within the previous 12 h, with a clear ST-segment elevation of >0.1millivolt(mV) in ≥2 contiguous electrocardiographic leads, and the value of troponin I(TNI) above the maximum peak in the normal range.

• Age20-80,All genders

• The first myocardial infarction, and there is no history of PCI therapy and coronary artery bypass grafting

• The infarct-related artery(IRA) is totally occlusive

• Blood pressure is higher than 90/60 millimeters of mercury（mmHg）

• The time from myocardial infarction onset to reach the hospital is less than 12 hs

• Successful interventional treatment, the residual stenosis of IRA is less than 30% ,

• TIMI flow grade 3

Exclusion Criteria:

• kidney dysfunction (creatinine >2 mg/dl),

• History of previous liver disease,

• Cardiogenic shock,

• History of myocardial infarction (MI)

• History of coronary artery bypass grafting

• History of allergic response to drugs

• Right ventricular infarction

• Severe hypovolemia